Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

BACKGROUND: Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine modalities that can easily adapt to current and future developments in cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordy, James T., Luo, Kun, Zhang, Hong, Biragyn, Arya, Markham, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168589/
https://www.ncbi.nlm.nih.gov/pubmed/28018602
http://dx.doi.org/10.1186/s40425-016-0189-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168589/
https://www.ncbi.nlm.nih.gov/pubmed/28018602
http://dx.doi.org/10.1186/s40425-016-0189-y

Ejemplares similares